(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2019 (11.04.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/068904 A1

(51) International Patent Classification:
A61K 31/4184 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *A61P 35/02* (2006.01)
A61K 9/00 (2006.01) *A61P 35/04* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/EP2018/077214

(22) International Filing Date:
05 October 2018 (05.10.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17194987.8 05 October 2017 (05.10.2017) EP

(71) Applicant: **TUBE PHARMACEUTICALS GMBH** [AT/AT]; Leberstr. 20, 1110 Wien (AT).

(72) Inventor: **RICHTER, Wolfgang**; TUBE Pharmaceuticals GmbH, Leberstr. 20, 1110 Wien (AT).

(74) Agent: **RIDDERBUSCH, OSWIN, VOSSIUS & PARTNER**; Patentanwälte Rechtsanwälte mbB, Siebertstraße 3, 81675 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2019/068904 A1

(54) Title: ORAL BENDAMUSTINE FORMULATIONS

(57) Abstract: The present invention relates to an oral pharmaceutical composition comprising bendamustine in combination with a modified cyclodextrin, such as, e.g., methyl-ß-cyclodextrin or hydroxypropyl-ß-cyclodextrin. It has surprisingly been found in the context of the invention that such compositions exhibit a greatly improved oral bioavailability, which renders them particularly advantageous for oral therapeutic application, e.g., in the treatment of cancer.